HC Wainwright Boosts Earnings Estimates for Aethlon Medical

Aethlon Medical, Inc. (NASDAQ:AEMD) – Investment analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Aethlon Medical in a research note issued on Wednesday, February 19th. HC Wainwright analyst V. Bernardino now expects that the medical equipment provider will earn ($0.73) per share for the year, up from their previous forecast of ($0.92). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q4 2025 earnings at ($0.13) EPS and FY2026 earnings at ($0.49) EPS.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.09.

Separately, StockNews.com upgraded Aethlon Medical to a “sell” rating in a report on Wednesday.

Aethlon Medical Stock Down 4.3 %

Shares of Aethlon Medical stock opened at $0.58 on Friday. The firm has a market cap of $8.44 million, a price-to-earnings ratio of -0.37 and a beta of 1.88. The business has a fifty day simple moving average of $0.65 and a 200-day simple moving average of $0.49. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.85.

Institutional Investors Weigh In On Aethlon Medical

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth $25,000. Boothbay Fund Management LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth $186,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth $31,000. Virtu Financial LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth $81,000. Finally, Allegiance Financial Group Advisory Services LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth $26,000. 1.99% of the stock is owned by institutional investors and hedge funds.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.